Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NVM9
UPID:
INT13_HUMAN
Alternative names:
Cell cycle regulator Mat89Bb homolog; Germ cell tumor 1; Protein asunder homolog; Sarcoma antigen NY-SAR-95
Alternative UPACC:
Q9NVM9; B4DNK1; Q86WE2; Q96HM2; Q9BTX2; Q9NTB6; Q9NVM5
Background:
Integrator complex subunit 13, known by alternative names such as Cell cycle regulator Mat89Bb homolog, Germ cell tumor 1, Protein asunder homolog, and Sarcoma antigen NY-SAR-95, plays a pivotal role in the mitotic cell cycle and development. It is essential for dynein anchoring to the nuclear envelope, ensuring proper centrosome-nucleus coupling during prophase, and is implicated in spindle formation and cytokinesis at the G2/M phase. Additionally, it is a probable component of the Integrator complex, involved in snRNA U1 and U2 transcription and processing.
Therapeutic significance:
Understanding the role of Integrator complex subunit 13 could open doors to potential therapeutic strategies.